Local research ethics committees should review their approval of prevention trial

BMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7037.1036a (Published 20 April 1996) Cite this as: BMJ 1996;312:1036
  1. Catherine Read
  1. Science writer 33 Cockshutt Road, Beauchief, Sheffield S8 7DY

    EDITOR,—R D Bulbrook's editorial discusses who should take tamoxifen and for how long.1 The British aTTom (adjuvant tamoxifen treatment offer more) trial aims to recruit up to 20000 women with primary breast cancer. Many of these women could receive at least seven years' treatment with tamoxifen—two years more than the National Cancer Institute considers routinely advisable for …

    View Full Text

    Sign in

    Log in through your institution